CN Patent

CN118215481A — 晚期和/或转移性Trop-2过表达癌症患者的联合治疗

Assigned to Hainan Xiansheng Zaiming Pharmaceutical Co ltd · Expires 2024-06-18 · 2y expired

What this patent protects

本发明属于针对选定的难以治疗的癌症患者组的改进的组合治疗领域，包括例如患有晚期/转移性三阴性乳腺癌(TNBC)、复发性或转移性尿路上皮癌(mUC)的患者，或Trop‑2过表达癌症如非小细胞肺癌(NSCLC)，其中改进的组合包括使用曲拉西利和戈沙妥珠单抗，并且提供增加的总生存期和/或降低的毒性。

USPTO Abstract

本发明属于针对选定的难以治疗的癌症患者组的改进的组合治疗领域，包括例如患有晚期/转移性三阴性乳腺癌(TNBC)、复发性或转移性尿路上皮癌(mUC)的患者，或Trop‑2过表达癌症如非小细胞肺癌(NSCLC)，其中改进的组合包括使用曲拉西利和戈沙妥珠单抗，并且提供增加的总生存期和/或降低的毒性。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN118215481A
Jurisdiction: CN
Classification: —
Expires: 2024-06-18
Drug substance claim: No
Drug product claim: No
Assignee: Hainan Xiansheng Zaiming Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.